How I treat acute chest syndrome in children with sickle cell disease

Area of Science:

• Pediatrics
• Hematology
• Pulmonology

Background:

• Acute chest syndrome (ACS) is a severe complication in children with sickle cell disease (SCD).
• ACS is characterized by new respiratory symptoms, pulmonary infiltrates, and often requires hospitalization.
• Etiologies include infection and pulmonary fat embolism (PFE), but are frequently multifactorial or obscure.

Purpose of the Study:

• To outline the clinical presentation, diagnosis, and management of acute chest syndrome in pediatric SCD patients.
• To provide guidance on therapeutic interventions, including antibiotics, oxygenation, hydration, and transfusion strategies.
• To discuss the role of corticosteroids and long-term management with hydroxyurea.

Main Methods:

• Review of clinical findings for diagnosis.
• Guidance on therapeutic interventions based on clinical presentation.
• Discussion of evidence for various treatment modalities.

Main Results:

• Therapy initiation should be guided by clinical findings.
• Standard management includes macrolide antibiotics, oxygen, hydration, and simple transfusion.
• Partial exchange transfusion is reserved for specific cases of worsening respiratory status with mild anemia.
• Corticosteroid therapy warrants further investigation in clinical trials.

Conclusions:

• Prompt initiation of appropriate therapy is crucial for managing ACS in pediatric SCD.
• Standard treatments include antibiotics, oxygen, hydration, and transfusions.
• Hydroxyurea should be considered post-recovery to reduce recurrent ACS episodes.